Heart Failure Clinical Trials in Dallas, Texas

30 studies are recruiting for heart failure in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

    Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…

    Stage
    Phase 3
    Ages
    40 and older
    Site
    Research Site, Dallas, Texas
    Locations
    957 in total
    Run by
    AstraZeneca
  2. A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

    Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Dallas, TX Investigative Site 10042, Dallas, Texas
    Locations
    356 in total
    Run by
    Colorado Prevention Center
  3. Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

    The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.

    Stage
    Not phased
    Ages
    18 to 100
    Site
    Baylor University Medical Center, part of Baylor Scott & White Health, Dallas, Texas
    Locations
    47 in total
    Run by
    BrioHealth Solutions, Inc.
  4. A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

    This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Texas Health Research and Education Institute, Dallas, Texas
    Locations
    588 in total
    Run by
    Boehringer Ingelheim
  5. Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

    This study aims to compare the efficacy of vericiguat versus placebo on change in n-terminal pro-brain natriuretic peptide (NTproBNP) from baseline to Week 16 of the Base Period. The primary hypothesis is that vericiguat is superior to placebo in reducing NT-proBNP at Week 16 of the Base Period.

    Stage
    Phase 2
    Ages
    0 to 17
    Site
    Children's Health-The Heart Center ( Site 0015), Dallas, Texas
    Locations
    109 in total
    Run by
    Merck Sharp & Dohme LLC
  6. Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

    The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.

    Stage
    Phase 3
    Ages
    18 to 85
    Site
    Baylor University Medical Center, Dallas, Texas
    Locations
    205 in total
    Run by
    Cytokinetics
  7. Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

    The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…

    Stage
    Not phased
    Ages
    0 to 20
    Site
    University of Texas-Southwestern Medical Center Dallas, Dallas, Texas
    Locations
    52 in total
    Run by
    Duke University
  8. A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

    This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Texas Health Research and Education Institute, Dallas, Texas
    Locations
    652 in total
    Run by
    Boehringer Ingelheim
  9. Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    Stage
    Not phased
    Ages
    Any age
    Site
    Research site, Dallas, Texas
    Locations
    333 in total
    Run by
    Medtronic
  10. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

    This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Renal Disease Research Institute, Dallas, Texas
    Locations
    838 in total
    Run by
    Novo Nordisk A/S
  11. Alleviant ALLAY-HF Study

    Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.

    Stage
    Not phased
    Ages
    40 and older
    Site
    UT Southwestern, Dallas, Texas
    Locations
    93 in total
    Run by
    Alleviant Medical, Inc.
  12. CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)

    The purpose of this multi-center clinical trial is to study the efficacy and safety of providing nutritional support added to the study-defined standard of care which consists of standardized dietary education and a single dietary counseling session shortly after discharge, versus study-defined sta…

    Stage
    Not phased
    Ages
    60 and older
    Site
    VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas, Texas
    Locations
    16 in total
    Run by
    VA Office of Research and Development
  13. Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

    There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: 1. To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 days of sup…

    Stage
    Phase 2
    Ages
    0 to 16
    Site
    Children's Health Dallas, Dallas, Texas
    Locations
    5 in total
    Run by
    Stanford University
  14. Assessment of CCM in HF With Higher Ejection Fraction

    The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor Scott and White Research Institute, Dallas, Texas
    Locations
    105 in total
    Run by
    Impulse Dynamics
  15. A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

    This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…

    Stage
    Phase 2
    Ages
    40 to 84
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    117 in total
    Run by
    Novo Nordisk A/S
  16. PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

    This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Medical City Healthcare Dallas, Dallas, Texas
    Locations
    48 in total
    Run by
    Endotronix, Inc.
  17. Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

    The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Baylor University Hospital, Dallas, Texas
    Locations
    68 in total
    Run by
    Abbott Medical Devices
  18. Home-based Cardiac Rehabilitation in Heart Failure

    This study evaluates a mobile health (mHealth) home-based cardiac rehabilitation program for patients with heart failure. We will stratify randomization between rural and urban populations, with the goal to assess implementation of cardiac rehabilitation across these two geographic areas. . The stu…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    2 in total
    Run by
    University of Texas Southwestern Medical Center
  19. IEEM-Heat and Heart Failure

    We will test the hypothesis that increasing skin wetness, and thus evaporative cooling, will attenuate the increase in core body temperature and accompanying cardiac stress during heat wave conditions in individuals with congestive heart failure. Secondly, we propose that wearing a water-saturated …

    Stage
    Not phased
    Ages
    45 and older
    Site
    Institute for Exercise and Environmental Medicine - Texas Health Presbyterian Hospital Dallas, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  20. Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes

    A pragmatic electronic health record (EHR) based randomized controlled trial to evaluate the utility of providing Ultromics EchoGo analysis results and recommendations for HF risk prevention therapies using an EHR embedded clinical decision support tool.

    Stage
    Not phased
    Ages
    Any age
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  21. Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease

    Powerful new drugs that can prevent or delay end stage kidney disease (ESKD) - so called sodium-glucose cotransporter-2 inhibitors (SGLT2i) - are now available for patients with type 2 diabetes. Whether these drugs have similar effects in patients with type 1 diabetes (T1D) remains unknown because …

    Stage
    Phase 3
    Ages
    18 to 75
    Site
    University of Texas Southwestern, Dallas, Texas
    Locations
    19 in total
    Run by
    Alessandro Doria
  22. XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

    The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    14 in total
    Run by
    XVIVO Perfusion
  23. Efficacy of LoDoCo in Improving Exercise Capacity Among Patients With HFpEF and Inflammation

    The purpose of this research study is to determine the effectiveness of low dose colchicine (LoDoCo) on measures of exercise capacity, physical function, frailty, and quality of life, among patients with heart failure with chronic stable preserved ejection fraction (HFpEF) and systemic inflammation…

    Stage
    Phase 2
    Ages
    50 and older
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  24. NT-ProBNP-based Heart Failure Screening and Prevention Trial in Patients With Type 2 Diabetes: STRONG-DM Study

    A pragmatic, randomized clinical trial to evaluate the effect of a heart failure (HF) risk assessment and prevention strategy incorporating HF clinical risk scores (WATCH-DM) with cardiac biomarker (NT-proBNP) paired with a clinical decision support tool to implement an intensive prevention strateg…

    Stage
    Not phased
    Ages
    Any age
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center
  25. Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

    This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).

    Stage
    Phase 2
    Ages
    18 to 90
    Site
    Baylor University Medical Center, Dallas, Texas
    Locations
    3 in total
    Run by
    Baylor Research Institute

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.